T1	Participants 90 129	patients with primary biliary cirrhosis
T2	Participants 235 274	patients with primary biliary cirrhosis
T3	Participants 803 814	32 patients
T4	Participants 816 851	18 ursodeoxycholic acid, 14 placebo
